2024
EP.12A.28 Overall Survival in a U.S. Asian Population with EGFR-Mutated Stage IV NSCLC Treated with Any Generation of TKIs as First-Line Treatment
Liu Y, Ma Z, Moreira A, Chachoua A, Velcheti V, Lau S, Punekar S, Sabari J, Shum E. EP.12A.28 Overall Survival in a U.S. Asian Population with EGFR-Mutated Stage IV NSCLC Treated with Any Generation of TKIs as First-Line Treatment. Journal Of Thoracic Oncology 2024, 19: s631-s632. DOI: 10.1016/j.jtho.2024.09.1187.Peer-Reviewed Original ResearchOverall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR mutations treated with first-line (1L) osimertinib (Osi) compared to earlier generation (Gen) of TKIs or sequential treatment (Tx).
Liu Y, Ma Z, Moreira A, Chachoua A, Velcheti V, Lau S, Punekar S, Sabari J, Shum E. Overall survival (OS) in a u.s. Asian population with stage IV NSCLC with EGFR mutations treated with first-line (1L) osimertinib (Osi) compared to earlier generation (Gen) of TKIs or sequential treatment (Tx). Journal Of Clinical Oncology 2024, 42: e20597-e20597. DOI: 10.1200/jco.2024.42.16_suppl.e20597.Peer-Reviewed Original ResearchNon-small-cell lung cancerTyrosine kinase inhibitorsStage IV non-small-cell lung cancerIV non-small-cell lung cancerOverall survivalCox proportional-hazards modelRetrospective studyProportional-hazards modelMedian OSMetastatic non-small-cell lung cancerHazard ratioIRB-approved retrospective studyMultivariate Cox proportional-hazards modelProgression-free survivalYears of follow-upKaplan-Meier methodLog-rank testAssess survival differencesCalculate hazard ratiosFLAURA trialL858R patientsNSCLC ptsSequential afatinibSuperior OSEGFR mutationsConsolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study
Nassar A, Kim S, Aredo J, Feng J, Shepherd F, Xu C, Kaldas D, Gray J, Dilling T, Neal J, Wakelee H, Liu Y, Lin S, Abuali T, Amini A, Nie Y, Patil T, Lobachov A, Bar J, Fitzgerald B, Fujiwara Y, Marron T, Thummalapalli R, Yu H, Owen D, Sharp J, Farid S, Rocha P, Arriola E, D'Aiello A, Cheng H, Whitaker R, Parikh K, Ashara Y, Chen L, Sankar K, Harris J, Nagasaka M, Ayanambakkam A, Velazquez A, Ragavan M, Lin J, Piotrowska Z, Wilgucki M, Reuss J, Luders H, Grohe C, Baena Espinar J, Feiner E, Punekar S, Gupta S, Leal T, Kwiatkowski D, Mak R, Adib E, Naqash A, Goldberg S. Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort Study. Journal Of Thoracic Oncology 2024, 19: 928-940. PMID: 38278303, DOI: 10.1016/j.jtho.2024.01.012.Peer-Reviewed Original ResearchTreatment-related adverse eventsConcurrent chemoradiationConsolidation therapyConsolidation durvalumabOverall survivalEGFR-mutant non-small-cell lung cancerAny-grade TRAEsCommon Terminology Criteria for Adverse Events versionFollow-upReal-world progression-free survivalObservational cohortNon-small-cell lung cancerPatients treated with osimertinibEGFR tyrosine kinase inhibitorsMedian duration of treatmentMulticenter retrospective cohort studyMultivariate Cox regression analysisDefinitive concurrent chemoradiationInternational retrospective analysisOptimal consolidation therapySensitive EGFR mutationsTreated with durvalumabAdverse Events versionProgression-free survivalStage III NSCLC
2021
Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma
Shah P, Punekar S, Pavlick A. Response to immune checkpoint inhibitor rechallenge after high-grade immune related adverse events in patients with advanced melanoma. Melanoma Research 2021, 31: 242-248. PMID: 33741813, DOI: 10.1097/cmr.0000000000000730.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsProgression-free survivalHigh-grade immune-related adverse eventsImmune checkpoint inhibitorsOverall survivalDisease progressionAdverse eventsAdvanced melanomaInitial irAEImmune checkpoint inhibitor rechallengeImmune related adverse eventsMedian progression-free survivalUnresectable stage III melanomaMedian overall survivalPercent of patientsRelated adverse eventsStage III melanomaLimited clinical evidenceRisk-benefit profileContinuation of treatmentNYU Langone HealthICI initiationICI rechallengeICI therapyCheckpoint inhibitors
2020
Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database
Punekar S, Kaakour D, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a Novel Entity of G3 (High-grade Well-differentiated) Colorectal Neuroendocrine Tumors (NET) in the SEER Database. American Journal Of Clinical Oncology 2020, 43: 846-849. PMID: 32910023, DOI: 10.1097/coc.0000000000000761.Peer-Reviewed Original ResearchConceptsG3 neuroendocrine tumorsColorectal neuroendocrine tumorsNeuroendocrine tumorsOverall survivalUnmarried patientsCox proportional hazards modelEnd Results (SEER) databaseGastrointestinal neuroendocrine tumorsPredictors of survivalPrognosis of patientsNational registry studyProportional hazards modelOlder patientsRegistry studySEER databaseWorse survivalMedian ageSurveillance EpidemiologyBlack patientsResults databaseTumor characteristicsHazards modelPatientsSmall studyLogistic regression
2019
Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors.
Punekar S, Masri-Lavine L, Hajdu C, Newman E, Becker D. Characterization of a novel entity of high-grade well-differentiated colorectal neuroendocrine tumors. Journal Of Clinical Oncology 2019, 37: e15696-e15696. DOI: 10.1200/jco.2019.37.15_suppl.e15696.Peer-Reviewed Original ResearchOverall survivalNeuroendocrine tumorsCarcinoid tumorsSmall cell neuroendocrine tumorsCox proportional hazards modelColorectal carcinoid tumorsEnd Results (SEER) databaseDemographics of patientsPredictors of survivalColorectal neuroendocrine tumorsNew pathologic entityProportional hazards modelPatient demographicsMedian ageSurveillance EpidemiologyBlack patientsResults databaseTumor characteristicsPathologic entityTumor gradeGI tractHazards modelPatientsSmall studyTumors